source
- Axiom's stem cell therapy shows zero mortality in phase-1 trial for newborn brain injuriesAxiom Biosciences reported that its mesenchymal stem cell (MSC) therapy achieved a 0% mortality rate over two years in a phase‑1 study of newborns with severe brain injuries. The nine‑patient trial…
- Baxter issues urgent correction for Volara breathing device circuits due to leak riskBaxter has sent an Urgent Medical Device Correction notice to customers using its Volara Positive Pressure Breathing System, advising that all patient circuits be corrected before further use. The…